Metabolic Aspects of Citrate Anticoagulation in Renal Replacement Therapy

• Conditions: Critical Illness; Acute Renal Failure

• Registration Number: NCT01361581
• Lead Sponsor: Charles University, Czech Republic

Brief Summary

Citrate anticoagulation is associated with metabolic side effects which are linked to a portion of citrate reaching systemic circulation. Data on significance of systemic gain of citrate and its relationship to method configuration are missing. Patient might also receive certain dose of lactate as a buffer and a dose of glucose if acid-citrate-dextrose solution is used. The authors test variable methods of indirect estimate of systemic dose of citrate which would allow to quantify the metabolic input without mostly unavailable measurements of citrate levels.

Detailed Description

Not available

Study Timeline

• Study Start: 2008-01
• Status Verified: 2011-05
• Study First Submitted: 2011-05-25
• Study First Submitted QC: 2011-05-26
• Last Update Submitted: 2011-05-26
• Study First Posted: 2011-05-27
• Last Update Posted: 2011-05-27

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

• Acute renal failure on continuous renal replacement therapy for more than 24 hours (CVVH or CVVHDF).

Exclusion Criteria

• Absence of consent.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

Dept of Anaesthesia and Intensive Care, General University Hospital, 1st Medical Faculty, Charles University; 🇨🇿 Prague 2, Czech Republic